Coronary collateral quantitation in patients with coronary artery disease using intravascular flow velocity or pressure measurements

Inselspital, Universitätsspital Bern, Berna, Bern, Switzerland
Journal of the American College of Cardiology (Impact Factor: 15.34). 11/1998; 32(5):1272-1279. DOI: 10.1016/S0735-1097(98)00384-2

ABSTRACT Objectives. This study evaluated two methods for the quantitative measurement of collaterals using intracoronary (IC) blood flow velocity or pressure measurements.Background. The extent of myocardial necrosis after coronary artery occlusion is substantially influenced by the collateral circulation. So far, qualitative methods have been available to assess the human coronary collateral circulation, thus restraining the conclusive investigation of, for example, therapies to promote collateral development.Methods. Fifty-one patients with a coronary artery stenosis to be treated by percutaneous transluminal coronary angioplasty (PTCA) were investigated using IC PTCA guidewire-based Doppler and pressure sensors positioned distal to the stenosis. Simultaneous measurements of aortic pressure, IC velocity and pressure distal to the stenosis during and after PTCA provided the variables for calculating collateral flow indices (CFIv and CFIp) that express collateral flow as a fraction of flow via the patent vessel. Both CFIv and CFIp were compared with conventional methods for collateral assessment, among them ST-segment changes >1 mm on IC and surface electrocardiogram (ECG) at PTCA. Also, CFIv and CFIp were compared with each other.Results. In 11 patients without ECG signs of ischemia during PTCA (sufficient collaterals), relative collateral flow amounted to 46% as determined by Doppler and pressure wire. Patients with insufficient collaterals (n = 40) had relative collateral flow values of 18%. Using a threshold of CFI = 30%, sufficient and insufficient collaterals could be diagnosed with 100% sensitivity and 93% specificity by IC Doppler, and 75% sensitivity and 92% specificity by IC pressure measurements. The agreement between Doppler and pressure measurements was good: CFIv = 0.08 + 0.8 CFIp, r = 0.80, p = 0.0001.Conclusions. Intracoronary flow velocity or pressure measurements during routine PTCA represent an accurate and, at last, quantitative method for assessing the coronary collateral circulation in humans.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The microvasculature is an immense organ that defines the environmental conditions within tissues in both health and disease, and is vital for the proper functions of all tissues. Here, we describe existing tools to study vascular cell function and our work using one platform of in vitro microvessels, which we employed to study vessel structure and remodeling, endothelial barrier function, angiogenesis, interactions between endothelial cells and perivascular cells, interactions between blood cells and the endothelium, and microvascular thrombosis. We also briefly discuss the potential future applications of these platforms in biology and medicine.
    Journal of Thrombosis and Haemostasis 06/2013; 11(s1). DOI:10.1111/jth.12245 · 5.55 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background—The function of naturally existing internal mammary- (IMA) to-coronary artery bypasses and its quantitative effect on myocardial ischemia is unknown. Methods and Results—The primary endpoint of this study was collateral flow index (CFI) as obtained during two 1-minute coronary artery balloon occlusions, i.e., the first with and the second without simultaneous distal IMA occlusion. The secondary study endpoint was the quantitatively determined intracoronary (i.c.) ECG ST segment elevation. CFI is the ratio between simultaneously recorded mean coronary occlusive pressure divided by mean aortic pressure both subtracted by mean central venous pressure. A total of 180 pairs of CFI measurements were performed among 120 patients. With and without IMA occlusion, CFI was 0.110±0.074 and 0.096±0.072, respectively (p<0.0001). The difference in CFI as obtained in the presence minus CFI in the absence of IMA occlusion was highest and most consistently positive during left IMA with left anterior descending artery (LAD), and during right IMA with right coronary artery (RCA) occlusion (ipsilateral occlusions): +0.033±0.044 and +0.025±0.027. This CFI difference was absent during right IMA with LAD, and during left IMA with RCA occlusion (contralateral occlusions): -0.007±0.034 and +0.001±0.023 (p=0.0002 vs ipsilateral occlusions). The respective CFI differences during either IMA with left circumflex artery (LCX) occlusions were inconsistently positive. I.c. ECG ST segment elevations were significantly reduced during ipsilateral IMA occlusions, but not during contralateral or LCX occlusions. Conclusions—There is a functional, ischemia-reducing extracardiac coronary artery supply via ipsilateral but not via contralateral natural internal mammary artery bypasses. Clinical Trial Registration Information— Identifier: NCTO1676207.
    Circulation 04/2014; DOI:10.1161/CIRCULATIONAHA.114.008898 · 14.95 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Well developed coronary collateral vessels in patients with symptomatic coronary artery disease (CAD) were shown to be associated with reduced future cardiovascular morbidity and mortality. However, the majority of patients with CAD lack adequate functional coronary collateral circulation. Stimulation of collateral vessel development by angiogenic growth factor therapy (therapeutic angiogenesis,TA) has been tested in many clinical trials in the past, but the potential of this new treatment paradigm has not been realized yet in late stage clinical trials. Mechanistic insights into collateral vessel development and the collective clinical experience in the past decade identified specific obstacles which might have impeded the progress in the field. This review identifies some of the key conceptual, technical and clinical hurdles, and recommends strategies to overcome them in future clinical trials.
    Journal of cardiovascular pharmacology 04/2014; DOI:10.1097/FJC.0000000000000107 · 2.11 Impact Factor

Full-text (2 Sources)

Available from
May 21, 2014